Healthcare Providers' Perspectives on the Role of Artificial Intelligence in the Care of Patients with Inflammatory Bowel Disease: An International Survey

Background Artificial intelligence (AI) is transforming inflammatory bowel disease (IBD) care, but concerns over data quality, privacy, and provider familiarity remain. Aims To examine international health care providers' (HCPs) perceptions, clinical use of, and barriers to applying AI in IBD care. Methods An anonymous 17-item survey was developed and pretested by an international team. The survey was fielded internationally from January to May 2025 via social media, international IBD newsletters and email listservs. Results Of 323 IBD professionals from North America (35.3%), Europe (26.0%), Asia-Pacific (19.2%), 207 (64.1%) viewed AI as very or extremely promising. AI-assisted endoscopy was reportedly adopted by 131 (40.6%) of respondents, but only 69 (21.4%) reported applying AI in IBD care or research. Males supported AI in IBD endoscopic scoring (89.9% vs. 79.1%, p = 0.009) and radiomics more than females (86.6% vs. 75.2%, p = 0.022), while females endorsed AI for patient education more than males (81.5% vs. 70.6%, p = 0.026). 145 (44.9%) respondents were concerned about AI usage in IBD care. Females were less concerned about cost (18.5% vs. 30.1%, p = 0.019) and more concerned about oversight (28.7% vs. 14.7%, p = 0.003). Concerns regarding AI usage decreased with age (OR 0.021 for age > 55 compared to age 25-34 years old; 95% CI 0.13-0.84). Exposure to IBD-focused AI-based tools was associated with more favorable perceptions of AI use in IBD care (OR 2.63, 95% CI 1.25-5.53). Conclusion Based upon survey results, HCPs had concerns over insufficient education, regulatory ambiguity, and perplexing implementation strategies for AI. Proven clinical benefit (74.9%) and adequate AI training (72.1%) are the top solutions for enabling the appropriate adoption of AI tools in IBD.